Skip navigation
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

Novel Therapies meetings & conferences

8 meetings & conferences listed in Novel Therapies 

XVI International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2015)

XVI International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2015)

7-9 September 2015, Sydney, Australia

The meeting will be of interest to all Haematologists and Clinicians, Researchers, and will include talks on:

• Molecular biology

• Cellular biology

• Prognostication

• Novel therapies

• CLL Clinical trials

Hematologist, Physician, Physician Researcher
7th World Congress on Ovulation Induction

7th World Congress on Ovulation Induction

3-5 September 2015 Bologna, Italy

Ovulation induction remains the cornerstone of therapeutic procedures used for the treatment of infertility, such as assisted reproduction and the management of anovulation. Due to Innovative drugs and regimens introduced in the last few years, ovulation induction is becoming increasingly more efficacious, cost effective, and safe. The 7th World Congress on Ovulatlon lnductlon will be an outstanding opportunity to learn and discuss these new developments with intemational key opinion leaders in this field.

Gynecologist, Physician Researcher
5th Annual Traumatic Brain Injury Conference
United States
Washington, DC

5th Annual Traumatic Brain Injury Conference

April 15-16, 2015 Washington, DC

Now in its 5th year, Arrowhead's Annual Traumatic Brain Injury Conference brings together researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury.

Key Themes

• Current Clinical Management of TBI

• Large-scale Observational Studies of TBI

• Advances and Opportunities for TBI Biomarkers

• Neuroimaging Research and Practice

• Biomarkers for Monitoring Response to TBI Treatments

• Learning From Other CNS disorders/Diseases

• TBI Clinical and Preclinical Trials and Models

• Emerging Tools for Diagnosis and Assessment of Brain Injuries

• Outcomes Research

This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors. At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another.

The 2015 Conference

Following up on 2014’s successful conference and record-breaking attendance, the 2015 event will bring together the world’s leading TBI researchers and thought leaders to discuss the following:

• Clinical case studies to showcase gaps in treatment and discuss possible solutions

• Advances in neuroimaging (PET imaging, volumetric MRI, etc.)

• Lessons learned from failed TBI clinical trials

• Giving voice to the patient community

• TBI and CTE outcomes research

• TBI-related dementia and neurodegenerative diseases

• Use of biomarkers as surrogate outcome measures in TBI trials

• Biomarkers in diagnosis and drug development in TBI

• TBI international initiatives and natural history studies

• Challenges and solutions in the diagnosis of sport-related concussions

• Review of TBI pharmacology and product candidates in the pipeline

Key Questions Answered

• How can animal model results translate to clinical research?

• What are the key patient populations for future clinical trials?

• What outcomes should new clinical trials measure?

• How can companion diagnostics and biomarkers improve therapeutic interventions and outcome prediction?

• What are the regulatory barriers facing developers of both companion diagnostics and new therapies?

Neurologist, Neuroscientist, Pharmacologist, Physician Researcher
Mechanisms of Neurodegeneration

Mechanisms of Neurodegeneration

Sunday 14 June - Wednesday 17 June 2015 European Molecular Biology Laboratory Heidelberg, Germany


• Mechanisms of neuronal and cognitive dysfucntion

• RNA, RNA binding proteins and RNA translation

• Chaperones, autophagy and mitochondria

• Disease progression

• Novel therapeutic approaches

• Translating to the clinic

Neurodegenerative diseases represent a major challenge for today’s society in terms of the large and rapidly increasing number of the population that are afflicted and the general lack of effective treatments. The emphasis of this symposium will be on the genetic, cellular and molecular basis of neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s, Amyotrophic Lateral Sclerosis and Prion disease. The meeting will cover the major mechanisms linked to neurodegeneration and highlight the similarities and differences between the diseases. A strong emphasis will be placed on the development of targeted drug therapies and potential treatment options.

This meeting aims to bring together basic and clinical research scientists working on different forms of neurodegeneration with their counterparts from the biotechnology and pharma industry to apply recent insights gained in the mechanisms of neurodegenerative diseases and the development of drug therapies. This symposium will bridge the gap between basic research and medical research in an area that urgently requires therapeutic progress, and emphasise the public health challenges in a public forum with senior public heath officials, research scientists, industry representatives and patient advocates.

Neurologist, Neuroscientist, Physician, Physician Researcher
Beige and Brown Fat: Basic Biology and Novel Therapeutics
United States

Beige and Brown Fat: Basic Biology and Novel Therapeutics

April 17—22, 2015 Snowbird, Utah

The epidemic of obesity and diabetes has become a world-wide health risk. These metabolic disorders are a direct threat to the health and economic well-being of many nations. Unfortunately, education about diet and exercise are not sufficient to meet this emergency and new therapies are badly needed. Brown fat has emerged as one of the few genuinely new approaches to these problems. Brown fat exists in most or all adult humans and can dissipate caloric energy and improve both obesity and diabetes in experimental animals. This meeting will focus on new pathways controlling brown fat development and thermogenesis. We will delve into the types of brown fat cells, beige, classical brown and others. We will also put a special emphasis on emerging approaches, both biological and chemical, that can manipulate these cells for therapeutic purposes. It is our hope and belief that this meeting can nucleate expanded efforts in both academia and pharma to explore this promising research area. There has not been a Keystone Symposia conference dedicated to brown fat. While there has been a session here and there at the Obesity meeting, the science and the biomedical needs warrant this new and focused conference. Of course, this will also bridge the Obesity and Diabetes communities, and lead to pharma/academic collaborations.

Biologist, Cell Biologist, Molecular Biologist, Physician Researcher
4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community
United States

4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community

February 5-7, 2015 Santa Clara, California

The 4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community, will be held February 5-7, 2015 at the Marriott Santa Clara, 2700 Mission Boulevard, Santa Clara, CA 95054.

This conference is the updated continuation of the Coma to Community Conference hosted by Santa Clara Valley Medical Center from 1977 through 1995.  We anticipate an audience of 500 rehabilitation professionals representing a variety of disciplines as well as individuals with brain injury, family members, and caregivers.  Our previous conferences were endorsed by the American Congress of Rehabilitation Medicine and the Brain Injury Association of America, and the International Brain Injury Association.

The main conference includes two days of multi-disciplinary state of the art educational sessions focusing on issues related to acquired brain injury treatment and research in both a military and civilian population.  The 2015 conference will feature multiple half-day pre-conference workshops as an optional add-on.

The 2015 main conference will focus on:

1. Medical Complexity and Acute and Chronic Treatment (successful strategies and new approaches)

2. Innovative Interventions and Assistive Devices (new technology, stem cells and others)

3. Living After Brain Injury (socialization, relationships, advocacy and caregiving)

4. Special Populations (military and veteran issues, cultural competence, dual diagnosis, pediatrics, and aging

The conference curriculum will appeal to social workers, therapists, psychologists, physiatrists, nurses, researchers, administrators, advocates, individuals with brain injury and family members affected by brain injury.  Presentation formats will include lectures, panel discussions, and interactive workshops.  Peer reviewed symposia and poster presentations will be an integral part of the program allowing for the sharing of information regarding research and innovative multidisciplinary treatment approaches.  We will be offering CME's for the main conference and CME's for the pre-conferences for a variety of disciplines.

In addition to faculty, comprised of nationally and internationally recognized leaders in the field of brain injury and rehabilitation, there will be exhibitors sharing the latest innovations and information regarding services for individuals with brain injury and their families.

Family Caregiver, Neurologist, Neuroscientist, Nurse, Nurse Researcher, Pediatric Nurse, Pediatrician, Physiatrist, Physical Therapist, Physician, Physician Researcher, Social Worker
8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015)

8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015)

February 18-21, 2015 Paris, France

The 8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015) follows the success of previous meetings including ATTD 2014 which attracted 2,084 participants from 80 countries, where all participants agreed that this is the main networking event in the field!

ATTD 2015 will attract an international audience of researchers and clinicians from the fields of diabetes, endocrinology and metabolism, diabetes technology developers as well as general & family medicine practitioners.

Join us for ATTD 2015 in the beautiful city of light, Paris, France, on February 18-21, 2015 for this conference which focuses on a unique niche and offers unparalleled networking opportunities.

Biomedical Engineer, Endocrinologist, Family Physician, Informatician, Internist, Physician, Physician Researcher, Technologist
Eleventh International Kawasaki Disease Symposium
United States

Eleventh International Kawasaki Disease Symposium

Feb. 3-6, 2015 Honolulu, Hawaii

This 3 ½ day conference includes lectures, discussions, and oral/poster presentations focusing on the latest advances in Kawasaki disease. Kawasaki disease is the major cause of acquired childhood heart disease in developed countries. Children who develop significant coronary artery aneurysms as a result of Kawasaki disease have a lifetime increased risk of myocardial ischemia, infarction, and sudden death. The study of Kawasaki disease and its treatment are likely to yield important answers to general questions in cardiovascular health and disease that apply equally to pediatric and adult populations.

The Eleventh International Kawasaki Disease Symposium seeks to address the influence of genetics on disease susceptibility and outcomes, the mechanisms of coronary artery damage following severe acute inflammation, the role of immune modulation and other novel therapies in preventing artery damage, the potential use of serum biomarkers for diagnosis and prognosis, the use of newer imaging techniques to assess abnormalities of the coronary arteries and myocardium, and new therapies regarding anticoagulation and vascular health. Current data regarding the worldwide epidemiology will be highlighted, as well as psychosocial issues, guidelines and nursing practice .

Since the historic first International Kawasaki Disease Symposium in 1984, the international symposium has been held every 3 years in Japan, the United States, or Taiwan, drawing attendees from all continents.

Who Should Attend -  The audience will consist of pediatric and adult cardiologists, pediatricians and pediatric subspecialists in immunology, infectious disease, and rheumatology;  cardiovascular surgeons; pathologists; basic scientists in genetics, molecular biology, microbiology, and cardiovascular pathophysiology; public health officials from county and state agencies and the Center for Disease Control and Prevention; epidemiologists; and nurses working in pediatric cardiology and public health who have an interest in Kawasaki disease.


Summarize prevailing hypotheses regarding KD etiology, and discuss emerging research supporting or contradicting these hypotheses.

Summarize current findings regarding diagnostic and prognostic biomarkers for KD, and their potential significance to clinical practice.

Summarize the most recent research and clinical findings regarding genetic susceptibility to KD and to KD coronary artery disease.

Summarize the most recent research and clinical findings regarding IVIG mechanism of action and the efficacy of additional or alternative therapies

Review evidence regarding the two distinct arterial processes that can lead to myocardial ischemia or infarction.

Review available imaging modalities for their ability to assess for presence of thrombosis and luminal myofibroblastic proliferation.

Summarize technical principles and current evidence supporting use of various imaging modalities in determining KD prognosis and optimal long-term follow-up.

Review evidence regarding the efficacy, safety, and long-term expected outcomes of revascularization options for KD patients.

Review current understanding, recent findings, and unresolved issues regarding optimization of thromboprophylaxis in KD patients.

Cardiologist, Cardiothoracic Surgeon, Epidemiologist, Microbiologist, Molecular Biologist, Pathologist, Patient, Pediatrician, Public Health Expert, Public Health Worker, Surgeon